November 30, 2021
Epi Data Slicer – Axial Spondyloarthritis
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: the tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira,…
December 6, 2019
The axial spondyloarthritis market is undergoing rapid change as physicians increasingly recognize both ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-AxSpA)…
September 23, 2019
The axial spondyloarthritis (AxSpA) market dynamics are constantly shifting. The definition of the disease, once limited to ankylosing spondylitis (AS), has expanded beyond those with spinal…
December 6, 2018
February 13, 2018
November 18, 2016
July 27, 2016